Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer Full Text
Clinical Cancer Research, 05/16/2012
Rudin CM et al. – Bcl–2 targeting by navitoclax shows limited single–agent activity against advanced and recurrent small cell lung cancers (SCLC). Correlative analyses suggest several putative biomarkers of clinical benefit. Preclinical models support that navitoclax may enhance sensitivity of SCLC and other solid tumors to standard cytotoxics.